Abstract:The article presents the development of a novel messenger RNA (mRNA) vaccine targeting poxviridae infections. Through bioinformatics analysis and molecular simulations, the vaccine construct containing 28 antigenic epitopes was designed, with safety measures to avoid autoimmunity. The mRNA vaccine demonstrated promise, showing potential for preventing infections with Mpox and vaccinia viruses. Background Messenger RNA (mRNA) vaccines emerged as a powerful tool in the fight against infections. Unlike traditional vaccines, this unique type of vaccine elicits robust and persistent innate and humoral immune response with a unique host cell‐mediated pathogen gene expression and antigen presentation. Methods This offers a novel approach to combat poxviridae infections. From the genome of vaccinia and Mpox viruses, three key genes (E8L, E7R, and H3L) responsible for virus attachment and virulence were selected and employed for designing the candidate mRNA vaccine against vaccinia and Mpox viral infection. Various bioinformatics tools were employed to generate (B cell, CTL, and HTL) epitopes, of which 28 antigenic and immunogenic epitopes were selected and are linked to form the mRNA vaccine construct. Additional components, including a 5′ cap, 5′ UTR, adjuvant, 3′ UTR, and poly(A) tail, were incorporated to enhance stability and effectiveness. Safety measures such as testing for human homology and in silico immune simulations were implemented to avoid autoimmunity and to mimics the immune response of human host to the designed mRNA vaccine, respectively. The mRNA vaccine's binding affinity was evaluated by docking it with TLR‐2, TLR‐3, TLR‐4, and TLR‐9 receptors which are subsequently followed by molecular dynamics simulations for the highest binding one to predict the stability of the binding complex. Results With a 73% population coverage, the mRNA vaccine looks promising, boasting a molecular weight of 198 kDa and a molecular formula of C8901H13609N2431O2611S48 and it is said to be antigenic, nontoxic and nonallergic, making it safe and effective in preventing infections with Mpox and vaccinia viruses, in comparison with other insilico‐designed vaccine for vaccinia and Mpox viruses. Conclusions However, further validation through in vivo and in vitro techniques is underway to fully assess its potential.

mRNA vaccines: A promising platform for safer, more effective next-generation Orthopoxvirus immunization

Old and new mpox vaccine

Mpox mRNA-1769 Vaccine Inhibits Orthopoxvirus Replication at Intranasal, Intrarectal, and Cutaneous Sites of Inoculation

Comparison of protection against mpox following mRNA or modified vaccinia Ankara vaccination in nonhuman primates

Rational development of multicomponent mRNA vaccine candidates against mpox

An mpox quadrivalent mRNA vaccine protects mice from lethal vaccinia virus challenge

An mpox virus mRNA-lipid nanoparticle vaccine confers protection against lethal orthopoxviral challenge

Mpox virus mRNA-lipid nanoparticle vaccine candidates evoke antibody responses and drive protection against the Vaccinia virus challenge in mice

Mpox multi-antigen mRNA vaccine candidates by a simplified manufacturing strategy afford efficient protection against lethal orthopoxvirus challenge

A multivalent mRNA monkeypox virus vaccine (BNT166) protects mice and macaques from orthopoxvirus disease

Monkeypox virus quadrivalent mRNA vaccine induces antibody responses and cellular immunity and protects mice against Vaccinia virus

Evaluation and comparison of immune responses induced by two Mpox mRNA vaccine candidates in mice

mRNA-based monkeypox virus vaccine prevents disease in non-human primates

Monkeypox virus quadrivalent mRNA vaccine induces immune response and protects against vaccinia virus

Exploring computational approaches to design mRNA Vaccine against vaccinia and Mpox viruses

An overview on mRNA-based vaccines to prevent monkeypox infection

Single-chain A35R-M1R-B6R Trivalent Mrna Vaccines Protect Mice Against Both Mpox Virus and Vaccinia Virus

mRNA Vaccine Development for Emerging Animal and Zoonotic Diseases

Mpox global health emergency: Insights into the virus, immune responses, and advancements in vaccines PART II: Insights into the advancements in vaccines

Vaccines against mpox: MVA-BN and LC16m8

Proteomics-based vaccine targets annotation and design of subunit and mRNA-based vaccines for Monkeypox virus (MPXV) against the recent outbreak